[Featured Stock] Enzychem Lifesciences Hits Upper Limit on News of COVID-19 Treatment Development
[Asia Economy Reporter Minwoo Lee] Engchem Life Sciences recorded a limit-up following news that it is developing a treatment for the novel coronavirus infection (COVID-19).
As of 10:53 AM on the 17th, Engchem Life Sciences is showing a 29.84% increase from the previous day, trading at 62,000 KRW.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
Previously, Engchem Life Sciences announced that it had filed a patent application with relevant U.S. agencies to use its synthetic new drug substance 'EC-18' as a COVID-19 treatment. The company is also carefully reviewing efforts to obtain patents in major regions such as Japan, Europe, and China.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
